AARD|Aardvark Therapeutics Inc|Price:6.600|Chg%:+0.200

This article provides a detailed financial overview of Aardvark Therapeutics Inc (AARD), including real-time quotes, key financial figures, and market trends. It highlights the company's current stock performance, analyst ratings indicating a "Buy" with a target price of $14.00, and a company overview focusing on its clinical-stage biopharmaceutical development for metabolic diseases. The report also lists major shareholders and peer comparisons.